Evotec has been contracted to manage candidate APIs by Pierre Fabre

By Gareth Macdonald

- Last updated on GMT

Evotec gets compound management contract
Evotec gets compound management contract

Related tags Compound management Active ingredient Pharmacology

Evotec has been hired to manage candidate drug compounds by French privately-owned pharmaceutical firm Pierre Fabre.

The five year deal – financial terms of which were not disclosed – will see the German contract research organisation (CRO) manage Pierre Fabre’s library of potential active pharmaceutical ingredients (APIs) and collection plates.

The work will be based at Evotc’s purpose built facility in Toulouse, France according to CEO Mario Polywka.

We welcome Pierre Fabre as another partner who has entrusted their complete compound management needs.

This collaboration further validates our strategy to establish a state-of-the-art compound management operation out of Toulouse for the European market and cements our position as the world leader in outsourced compound management​.”

Compound interest

Evotec has been focused on expanding its compound management client base since October when it signed a deal with the US National Cancer Institute (NCI).

Under the €4.5 m ($4.9 m) contract with the NCI, Evotec was tasked with managing the organisation's library of early-phase candidate drug compounds.

At the time Evotec spokeswoman Gabriele Hansen told us the firm is hopeful the NCI contract would attract the attention of pharmaceutical firms interested in accessing the compounds.

History tells us that contracts with the National Institutes of Health, the NCI being one of the largest centres, attracts other collaborators, academics, non-profits, and commercial organizations, who want to access these high calibre collections​” she said.

She added that the firm aimed to attract “other prospective collaborators who are looking to build their own discovery collection while avoiding upfront costs and leveraging a proven partners capacities and capabilities.”

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers